Exclusive: Courier Health raises $16.5M Series A to help biopharma companies...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) As more specialty drugs hit the market, a startup just raised fresh funding to help biopharma companies...
View ArticleHouse speaker plans vote on Biosecure Act as part of China legislation push
House Speaker Mike Johnson (R-LA) on Monday pledged a vote this year on a bill targeting Chinese biotech contractors, providing fresh momentum to the legislation. Johnson listed the Biosecure Act among...
View ArticleClik here to view.
Pfizer CSO Mikael Dolsten to depart after 15 years leading drug giant's R&D
Mikael Dolsten, a longtime leader of drug R&D at one of the world’s biggest pharma giants, will depart his post as chief scientific officer at Pfizer, the company said Tuesday morning. The 15-year...
View ArticleFTC says PBMs ‘exercise vast control’ over healthcare in long-awaited report...
Federal antitrust regulators issued a report describing the PBM industry as highly concentrated among a handful of companies that use their market power to put pressure on clients and competitors, and...
View ArticleClik here to view.
Chinese drugmakers still lag in R&D depth despite outpacing Europeans in new...
China may have outranked Europe for the first time in the number of new medicines it developed through to launch last year. But analysts told Endpoints News that Europe still has the edge when it comes...
View ArticleClik here to view.
Biopharma’s 20 highest-paid CEOs of 2023, earning $20M+ pay packages
The best-paid CEOs of 2023 fall largely into two groups: They’re either running some of the world’s biggest drugmakers, or they were given huge incentive packages in their first year on the job or as...
View ArticleKymera's stock rises after derma investigation expands; Ligand buys Apeiron
Plus, news about AEON Biopharma, Moderna and Mitsubishi Tanabe: Sanofi expands dermatology trials: Kymera Therapeutics said that expanding the Phase 2 hidradenitis suppurativa and atopic dermatitis...
View ArticleClik here to view.
UniQure trumpets mid-stage data for Huntington's disease gene therapy
UniQure on Tuesday released new two-year data on its Huntington’s disease gene therapy called AMT-130, sending its stock $QURE up by more than 50%. Interim results from the Phase 1/2 trials showed nine...
View ArticleIntellia to respond to lawsuit over in vivo therapy patents
Intellia Therapeutics said it will respond to a lawsuit filed Monday in a Delaware federal court alleging it infringed on several of BlueAllele’s patents covering methods for targeted insertion of DNA...
View ArticleZevra to face FDA adcomm in August over previously rejected rare disease drug
The FDA’s recently created Genetic Metabolic Diseases Advisory Committee will meet on Aug. 2 to review Zevra Therapeutics’ arimoclomol as a treatment for the rare and fatal genetic disorder known as...
View ArticleSix big R&D questions for Pfizer as science chief Dolsten exits
The planned exit of longstanding Pfizer CSO Mikael Dolsten comes at a pivotal moment for the huge drugmaker. The Covid-19 vaccine aura has fully worn off, it’s made a spate of deals to reload its...
View ArticleAmgen shelves early-stage bispecific T cell engager
Amgen has stopped development of a Phase 1 bispecific T cell engager, a type of medicine that is core to its oncology portfolio and for which it has trademarked the BiTE acronym. The California...
View ArticleArcutis tacks on atopic dermatitis approval for Zoryve cream
The FDA approved Arcutis Biotherapeutics’ skin treatment Zoryve to treat mild to moderate atopic dermatitis in adults and some children, the company announced Tuesday. It’s the drug’s third approval in...
View ArticleClik here to view.
'Next-gen' biotech acquirers find M&A momentum in Q2
Is it prime time for the “next-gen” biopharma acquirers? The headlines have flourished since April. Genmab and Ono Pharmaceutical made their first acquisitions. Vertex inked its largest M&A deal...
View ArticleFlagship raises $3.6B for 25 new startups
Flagship Pioneering, the 25-year-old life sciences incubator and investor, has reeled in $3.6 billion to build another 25 or so companies, it said Wednesday morning. The new capital pool consists of...
View ArticleBiotech salary analysis: The best and worst paying biopharmas of 2023
The typical biopharma worker made $199,048 last year, according to an Endpoints News annual analysis of pay trends. Endpoints reviewed regulatory filings from hundreds of drugmakers and life sciences...
View ArticleHow the world's biggest pharma and biotech companies paid their typical...
Among the biopharma industry’s biggest employers, California’s Gilead Sciences had the highest median salary for its workforce, an Endpoints News analysis found. Endpoints tallied 2023 median employee...
View ArticleThe best-paying biotechs in the Bay Area, Boston and San Diego for 2023
As part of our analysis of CEO and employee pay in biopharma, Endpoints News analyzed median employee pay in 2023 at 177 life sciences companies. Sixty of the top 100 highest-paying companies were...
View ArticleIdeaya aims to raise $263M; Immuneel extends Series A with $12M
Plus, news about XyloCor, Pfizer, Evotech, Skyhawk Therapeutics, HepaRegeniX and Vyome: Ideaya Biosciences’ $263M public offering: The South San Francisco, CA-based biotech said Tuesday it will sell...
View ArticleCEO Noubar Afeyan on how Flagship’s newest fund could shape biotech’s future
Flagship Pioneering is known for creating startups that aim to answer broad scientific questions in medicine, sustainability and agriculture, a strategy it describes as “leaps.” On Wednesday, Flagship...
View Article